HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Accept Industry’s Grandfathered Ingredient Lists – NPA

This article was originally published in The Tan Sheet

You may also be interested in...



Herbalife Proposes FDA Use NDI Master Files To Reduce Notification Burden

Herbalife asks FDA to temper its position that every supplement product containing a new dietary ingredient require a full notification, instead proposing a streamlined process based around NDI master files.

“No Way” FDA Can Require NDI Notifications For All Supplements – McGuffin

The leader of the American Herbal Products Association is confident FDA will ultimately require notifications strictly for new dietary ingredients, not all supplements containing those ingredients.

NDI Safety Data Guidance Sets Evidence Bar Too High, Attorney Says

The new dietary ingredient notification draft guidance sets a higher standard for evidence needed to support NDI notifications, similar to that required for food additives approvals, a food and drug attorney says.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS125195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel